https://charts.traderzeitung.de/phases/US45773H4092 string(1449) "{"isin":"US45773H4092","name":"Inovio Pharmaceuticals Inc","stock_id_xnas":65845172,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.24,"close_at":"2026-09-21 15:27:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.245,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":0.4032},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.25,"close_at":"2026-09-22 14:07:00","complete":true,"perf_pct":0.4016},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.3,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":4},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.3,"close_at":"2026-09-23 01:44:00","complete":true,"perf_pct":0}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.255,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-3.4615},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Inovio Pharmaceuticals Aktie News & Nachrichten

[WKN: A400EJ | Symbol: INO]

Realtimekurs

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Inovio Pharmaceuticals gefunden werden.

Inovio Pharmaceuticals Nachrichtenticker öffnen

MT Newswires 13.08.2026 13:37 Uhr

Inovio Pharmaceuticals Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

--Jefferies stuft Inovio Pharmaceuticals von Halten auf Kaufen hoch und passt Kursziel von $1,80 auf $3 an

Größte Verlierer vorbörslich

Inovio Pharmaceuticals reicht gemischtes Shelf-Offering über 300 Millionen US-Dollar ein